AGP Executive Report
Last update: 10 hours agoHepatitis B Trial: Denmark’s University of Southern Denmark has approved a CDC-funded study in Guinea-Bissau involving 14,000 newborns. Half would not receive the hepatitis B vaccine at birth, but the trial cannot begin without final government authorization in Guinea-Bissau. The $1.6 million project has drawn strong ethical criticism because the birth dose can prevent lifelong infection. Regional Digital ID: Guinea-Bissau is among seven ECOWAS countries to launch the bloc’s biometric identity card. The regional goal is mutual acceptance at air, land and sea borders by December 2026.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.